Breaking News, Collaborations & Alliances

Boehringer Ingelheim, MD Anderson Form Virtual Cancer R&D Center

New potential gastrointestinal and lung cancer therapies from Boehringer’s pipeline will be combined with MD’s drug development capabilities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have entered a new multi-year partnership to conduct collaborative research to advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development Center will enable effective data sharing and analysis between the organizations.   The partnership is built on a flexible framework, allowing for projects to enter at different stages (resea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters